Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGELLAN-AMD: FYB203 vs Eylea in neovascular age-related macular degeneration
jRCT2080225278Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of baiama in exudative macular degeneration (2 arms), sponsored by Bioeq AG. Started Jul 2020; status: completed.
02
Drugs
baiama
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2080225278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225278.